Investor's Business Daily on MSN1h
These Biotech Stocks Aren't Profitable But Still Make Elite IBD 50A handful of biotech stocks made an elite list despite being unprofitable. But many show robust sales growth and constructive ...
After asset purchase from Travere, Mirum's Ctexli crosses FDA finish line in rare metabolic disorder
The approval makes chenodiol—already cleared for decades to treat radiolucent gallstones under the brand name Chenodal—the ...
Anaheim, Calif. — Medical manufacturers are seeing overall growth in the market as it continues to rebound from high levels of inventory from the COVID-19 pandemic and responds to new drug development ...
BLCO may be sold in 2025 to service the debt of majority shareholder BHC, and any sale will be at a premium to the current ...
The U.S. Food and Drug Administration approved Mirum Pharmaceuticals' genetic disorder drug on Friday, making it the first ...
The big pharma sector is one that’s generally fallen out of favor for many investors over the past few decades, as large ...
The FDA announcement confirms that the U.S. supply of both prescription-only drugs now meets or exceeds the current and ...
With a $430 million buyout of Australia’s Mayne Pharma locked down, Cosette Pharmaceuticals is looking to become a leading ...
The FDA’s decision will threaten the ability of compounding pharmacies to make far cheaper, unbranded versions of the ...
The Make America Healthy Again movement had a negative impact on pharmaceutical innovation and the corporations responsible for it.
David Ricks said drugs like Mounjaro and Zepbound are priced to reflect the costs involved, patent expiry, and the enormous ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback